Equities research analysts predict that Healthequity Inc (NASDAQ:HQY) will post sales of $68.79 million for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Healthequity’s earnings. The highest sales estimate is $70.12 million and the lowest is $67.61 million. Healthequity reported sales of $55.42 million in the same quarter last year, which indicates a positive year-over-year growth rate of 24.1%. The company is expected to announce its next earnings results on Tuesday, June 5th.
According to Zacks, analysts expect that Healthequity will report full-year sales of $281.11 million for the current year, with estimates ranging from $278.74 million to $284.80 million. For the next financial year, analysts forecast that the business will post sales of $341.72 million per share, with estimates ranging from $336.40 million to $348.90 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that cover Healthequity.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Monday, March 19th. The company reported $0.06 EPS for the quarter, meeting analysts’ consensus estimates of $0.06. Healthequity had a net margin of 20.64% and a return on equity of 13.47%. The business had revenue of $60.44 million for the quarter, compared to analysts’ expectations of $58.46 million.
Several research analysts have recently issued reports on HQY shares. Citigroup started coverage on shares of Healthequity in a report on Thursday, January 4th. They issued a “buy” rating on the stock. BidaskClub upgraded shares of Healthequity from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. JPMorgan Chase cut their target price on shares of Healthequity from $52.00 to $51.00 and set an “overweight” rating on the stock in a report on Wednesday, January 24th. Chardan Capital raised their target price on shares of Healthequity from $62.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 20th. Finally, Zacks Investment Research cut shares of Healthequity from a “buy” rating to a “hold” rating and set a $62.00 target price on the stock. in a report on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Healthequity presently has an average rating of “Buy” and an average target price of $66.50.
NASDAQ HQY traded down $0.87 on Friday, reaching $65.32. 344,740 shares of the company’s stock traded hands, compared to its average volume of 655,227. Healthequity has a 12 month low of $40.21 and a 12 month high of $68.75. The stock has a market capitalization of $4,028.32, a P/E ratio of 120.98, a PEG ratio of 2.65 and a beta of 1.39.
In other Healthequity news, CEO Jon Kessler sold 1,332 shares of the firm’s stock in a transaction on Wednesday, February 14th. The stock was sold at an average price of $55.00, for a total transaction of $73,260.00. Following the completion of the transaction, the chief executive officer now owns 446,332 shares of the company’s stock, valued at $24,548,260. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jon Soldan sold 995 shares of the firm’s stock in a transaction on Wednesday, March 28th. The shares were sold at an average price of $61.30, for a total value of $60,993.50. Following the transaction, the vice president now directly owns 9,433 shares of the company’s stock, valued at approximately $578,242.90. The disclosure for this sale can be found here. In the last quarter, insiders sold 750,831 shares of company stock worth $40,420,618. 29.00% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in HQY. Catalyst Capital Advisors LLC purchased a new position in Healthequity during the fourth quarter valued at $149,000. Two Sigma Securities LLC purchased a new position in Healthequity during the fourth quarter valued at $208,000. Exane Derivatives lifted its position in Healthequity by 78.6% during the fourth quarter. Exane Derivatives now owns 4,682 shares of the company’s stock valued at $218,000 after buying an additional 2,060 shares during the period. Xact Kapitalforvaltning AB purchased a new position in Healthequity during the fourth quarter valued at $220,000. Finally, Envestnet Asset Management Inc. purchased a new position in Healthequity during the third quarter valued at $273,000. 99.17% of the stock is owned by institutional investors and hedge funds.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.